nach oben

Diabetologia

Erschienen in:

01.06.2003 | Review

Diabetic dyslipidaemia: from basic research to clinical practice*

verfasst von: Dr. M.-R. Taskinen

Erschienen in: Diabetologia | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

The recognition that the increase of plasma triglyceride rich lipoproteins (TRLs) is associated with multiple alterations of other lipoproteins species that are potentially atherogenic has expanded the picture of diabetic dyslipidaemia. The discovery of heterogeneity within major lipoprotein classes VLDL, LDL and HDL opened new avenues to reveal the specific pertubations of diabetic dyslipidaemia. The increase of large VLDL 1 particles in Type 2 diabetes initiates a sequence of events that generates atherogenic remnants, small dense LDL and small dense HDL particles. Together these components comprise the atherogenic lipid triad. Notably the malignant nature of diabetic dyslipidaemia is not completely shown by the lipid measures used in clinical practice. The key question is what are the mechanisms behind the increase of VLDL 1 particles in diabetic dyslipidaemia? Despite the advances of recent years, our understanding of VLDL assembly and secretion is still surprisingly incomplete. To date it is still unclear how the liver is able to regulate the amount of triglycerides incorporated into VLDL particles to produce either VLDL 1 or VLDL 2 particles. The current evidence suggests that the machinery driving VLDL assembly in the liver includes (i) low insulin signalling via PI-3 kinase pathway that enhances lipid accumulation into "nascent " VLDL particles (ii) up-regulation of SREBP-1C that stimulates de novo lipogenesis and (iii) excess availability of "polar molecules" in hepatocytes that stabilizes apo B 100. Recent data suggest that all these steps could be fundamentally altered in Type 2 diabetes explaining the overproduction of VLDL apo B as well as the ability of insulin to suppress VLDL 1 apo B production in Type 2 diabetes.

Recent discoveries have established the transcription factors including PPARs, SREBP-1 and LXRs as the key regulators of lipid assembly in the liver. These observations suggest these factors as a new target to tailor more efficient drugs to treat diabetic dyslipidaemia.

Turner R C, Millns H, Neil HAW et al. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 316:823–828PubMed

Isomaa B, Lahti K, Almgren P et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMed

Zimmet P, Alberti KGMM, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787CrossRefPubMed

Haffner S M, Lehto S, Rönnemaa T et al. (1998) Mortality from coronary heart diseases in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMed

Malmberg K, Yusuf S, Gerstein H C et al. (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wawe myocardial infarction. Circulation 102:1014–1019PubMed

Executive summary of the third report of the National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497PubMed

Syvänne M, Taskinen M-R (1997) Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet 350 [Suppl 1]:20–23

Taskinen M-R (2001) Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 109:173–181CrossRef

Ginsberg HN (2002) New perspectives in atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 106:2137–2142CrossRefPubMed

10.

Packard CJ, Shepherd J (1997) Lipoprotein heterogeneity and apolipoprotein B metabolism. Aterioscler Thromb Vasc Biol 17:3542–3556

11.

Taskinen M-R (1987) Lipoprotein lipase in diabetes. Diabet/Metab Rev 3:551–570

12.

Kasim SE, Tseng K, Jen K-LC et al. (1987) Significance of hepatic triglyceride lipase activity in the regulation of serum high density lipoproteins in type II diabetes mellitus. J Clin Endocrinol Metab 65:183–187PubMed

13.

Baynes C, Henderson A D, Anyaoku V et al. (1991) The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Diabet Med 8:560–566PubMed

14.

Tan KCB, Shiu SWM, Chu BYM (1999) Roles of hepatic lipase and cholesteryl ester transfer protein determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 145:273–278CrossRefPubMed

15.

Tan CE, Forster L, Caslake MJ et al. (1995) Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vasc Biol 15:1839–1848PubMed

16.

McEneny J, O'Kane MJ, Moles KW et al. (2000) Very low density lipoprotein subfractions in type 2 diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 43:485–493CrossRefPubMed

17.

Taskinen M-R, Packard CJ, Shepherd J (1990) Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39:1017–1027PubMed

18.

Guérin M, Le Goff W, Lassel TS et al. (2001) Proatherogenic role of elevated CE transfer from HDL to VLDL 1 and dense LDL in type 2 diabetes. Arterioscler Thromb Vasc Biol 21:282–288PubMed

19.

Leinonen ES, Leinonen PJ, Salonen JT et al. (2002) Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 25:1807–1812PubMed

20.

Shachter NS (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12:297–304CrossRefPubMed

21.

Wang CS, McConathy WJ, Kloer HU et al. (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75:384–390PubMed

22.

Ebra T, Ramakrishnan R, Steiner G et al. (1997) Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein. Eur J Clin Invest 99:2672–2681

23.

Sehayek E, Eisenberg S (1991) Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266:18259–18267PubMed

24.

Briones ER, Mao SJ, Palumbo PJ et al. (1984) Analysis of plasma lipids and apolipoproteins in insulin-dependent and non-insulin-dependent diabetics. Metabolism 33:42–49PubMed

25.

Campos H, Perlov D, Khoo C et al. (2001) Distinct patterns of lipoproteins with apo B defined by presence of apo E or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 42:1239–1249PubMed

26.

Tomiyasu K, Walsh BW, Ikewaki K et al. (2001) Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol 21:1494–1500PubMed

27.

Sacks FM, Alaupovic P, Moye LA et al. (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102:1886–1892PubMed

28.

Luc G, Fievet C, Arveiler D et al. (1997) Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur Infarctus du Myocarde. J Lipid Res 37:508–517

29.

Gervaise N, Garrigue M A, Lasfargues G et al. (2000) Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type 2 diabetes. Diabetologia 43:703–708CrossRefPubMed

30.

Gabor J, Spain M, Kalant N (1980) Composition of serum very-low-density and high-density lipoproteins in diabetes. Clin Chem 26:1261–1265PubMed

31.

Stalenhoef AFH, Demacker PNM, Lutterman JA et al. (1982) Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. Diabetologia 22:489–491PubMed

32.

Ishibashi S, Yamada N, Shimano H et al. (1989) Composition of very-low-density lipoproteins in non-insulin-dependent diabetes mellitus. Clin Chem 35:808–812PubMed

33.

Mahley RW, Ji S-Z (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein. Eur J Lipid Res 40:1–16

34.

Syvänne M, Rosseneu M, Labeur C et al. (1994) Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: preliminary report. Atherosclerosis 105:25–34PubMed

35.

Tannock LR, Olin KL, Barret HR et al. (2002) Triglyceride-rich lipoproteins from subjects with type 2 diabetes do not demonstrate increased binding to biglycan, a vascular proteoglycan. J Clin Endocrinol Metab 87:35–40PubMed

36.

Sparks JD, Sparks CE (1994) Insulin regulation of triglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215:9–32CrossRefPubMed

37.

Zammit V A (1996) Role of insulin in hepatic fatty acid partitioning: emerging concepts. Biochem J 314:1–14PubMed

38.

Chirieac D V, Chirieac L R, Corsetti J P et al. (2000) Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Endocrinol Metab 279: E1003–E1011

39.

Lin MCM, Gordon D, Wetterau JR (1995) Microsomal triglyceride transfer protein (MTP) regulation in HEPG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 36:1073–1081PubMed

40.

Kuriyama H, Yamashita S, Shimomura I et al. (1998) Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27:557–562PubMed

41.

Bartels ED, Lauritsen M, Nielsen LB (2002) Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 51:1233–1239PubMed

42.

Taghibiglou C, Carpentier A, Van Iderstine SC et al. (2000) Mechanism of hepatic very low density lipoprotein overproduction in insulin resistance. J Biol Chem 275:8416–8425CrossRefPubMed

43.

Carpentier A, Taghibiglou C, Leung N et al. (2002) Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277:28795–28802CrossRefPubMed

44.

Marsh JB, Welty FK, Lichtenstein AH et al. (2002) Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 162:227–244CrossRefPubMed

45.

Packard CJ, Demant T, Stewart JP et al. (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41:305–317PubMed

46.

47.

Malmström R, Packard CJ, Watson TDG et al. (1997) Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454–1464PubMed

48.

Lewis GF, Uffelman KD, Szeto LW et al. (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL ApoB production in normal weight and obese individuals. Diabetes 42:833–842PubMed

49.

Bioletto S, Golay A, Munger R et al. (2000) Acute hyperinsulinemia and very-low-density lipoprotein subfractions in obese subjects. Am J Clin Nutr 71:443–449PubMed

50.

Malmström R, Packard CJ, Caslake M et al. (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454–462CrossRefPubMed

51.

Gibbons GF, Islam K, Pease RJ (2000) Mobilisation of triglycerol stores. Biochim Biophys Acta 1483:37–57CrossRefPubMed

52.

Olofsson S-O, Stillemark-Bilton P, Asp L (2000) Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med 10:338–345CrossRefPubMed

53.

Lewis GF, Carpentier A, Adeli K et al. (2002) Disordered fat storage and mobolization in the pathogenesis of insulin resistance ond type 2 diabetes. Endocr Rev 23:201–229PubMed

54.

Phung TL, Roncone A, De Mesy Jensen KL et al. (1997) Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. Journal of Biological Chemistry 272:30693–30702CrossRefPubMed

55.

Brown AM, Gibbons GF (2001) Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol 21:1656–1661PubMed

56.

Shimomura I, Matsuda M, Hammer RE et al. (2000) Decreased IRS-2 and increased SREBP-1 lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77–86PubMed

57.

Foufelle F, Ferré P (2002) New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol ragulatory element binding protein-1c. Biochem J 366:377–391CrossRefPubMed

58.

Matsumoto M, Ogawa W, Teshigawara K et al. (2002) Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 51:1672–1680PubMed

59.

Yahagi N, Shimano H, Hasty AH et al. (2002) Absence of sterol regulatory element-binding Protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice. J Biol Chem 277:19353–19357CrossRefPubMed

60.

Malmström R, Packard CJ, Caslake M et al. (1998) Effects of insulin and acipimox on VLDL 1 and VLDL 2 apolipoprotein B production in normal subjects. Diabetes 47:779–787PubMed

61.

Malmström R, Packard CJ, Caslake M et al. (1999) Effect of heparin-stimulated plasma lipolytic activity on VLDL apo B subclass metabolism in normal subjects. Atherosclerosis 146:381–390CrossRefPubMed

62.

Carpentier A, Patterson BW, Leung N et al. (2002) Sensitivity to acute insulin-mediated suppression of plasma free fatty acids is not a determinant of fasting VLDL triglyceride secretion in healthy humans. Diabetes 51:1867–1875PubMed

63.

Ginsberg HN (2000) Insulin resistance and cardiovascular disease. J Clin Invest 106:453–458PubMed

64.

Kissebah AH, Alfarasi S, Evans DJ et al. (1982) Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 31:217–225PubMed

65.

Taskinen MR, Beltz WF, Harper I et al. (1986) Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Study before and after sulfonylurea therapy. Diabetes 113:522–526

66.

Cummings MH, Watts GF, Umpleby AM et al. (1995) Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 38:959–967CrossRefPubMed

67.

Howard BV, Abbot WGH, Egusa G, Taskinen MR (1987) Coordination of very-low-density lipoprotein triglyceride and apolipoprotein B metabolism in humans: effect of obesity and non-insulin-dependent diabetes mellitus. Am Heart J 113:522–556PubMed

68.

Duvillard L, Pont F, Florentin E et al. (2000) Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 30:685–694CrossRefPubMed

69.

Ryysy L, Häkkinen A-M, Goto T et al. (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749–758PubMed

70.

Marchesini G, Brizi M, Bianchi G et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850PubMed

71.

Clark JM, Diehl AM (2002) Hepatic steatosis and type 2 mellitus. Current diabetes reports 2:210–215PubMed

72.

Seppälä-Lindroos A, Vehkavaara S, Häkkinen A-M et al. (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023–3028PubMed

73.

Yki-Järvinen H (2002) Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med 95 [Suppl 42]: 39–45

74.

De Vegt F, Dekker JM, Ruhé HG et al. (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia 42:926–931PubMed

75.

The Decode Study Group (2001) Glucose tolerance and cardiovascular mortality. Arch Intern Med 161:397–404PubMed

76.

Heine RJ, Balkau B, Ceriello A et al. (2003) What does post-prandial hyperglycaemia mean? Diabet Med (in press)

77.

De Man FHAF, Castro Cabezas N, van Barlingen HJJ et al. (1996) Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 26:89–108PubMed

78.

Ginsberg HN, Illingworth R (2001) Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 88 [Suppl]:H9–H15

79.

Syvänne M, Hilden H, Taskinen M-R (1994) Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 35:15–26PubMed

80.

Heine RJ, Dekker J M (2002) Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 45:461–475PubMed

81.

Schneeman BO, Kotite L, Todd KM et al. (1993) Relationship between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to fat containing meal in normolipidemic humans. Proc Natl Acad Sci USA 90:2069–2073PubMed

82.

Karpe F, Bell M, Björkegren J et al. (1995) Quantification of postprandial triglyceride-rich lipoproteins in healthy men by Retinyl Ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol. 15:199–207

83.

Vakkilainen J, Mero N, Schweizer A et al. (2002) Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 18:484–490CrossRefPubMed

84.

Karpe F, Olivercrone T, Hamsten A et al. (1997) Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J. Lipid Res 38:949–961

85.

Goldberg IJ, Kako Y, Lutz EP (2000) Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Curr Opin Lipidol 11:235–241CrossRefPubMed

86.

Tomkin GH, Owens D (2001) Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 17:27–43CrossRefPubMed

87.

Panarotto D, Rémillard P, Bouffard L et al. (2002) Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 32(2):84–92CrossRef

88.

Mero N, Suurinkeroinen L, Syvänne M et al. (1999) Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant; relationship to insulin sensitivity. J Lipid Res 40:1663–1670PubMed

89.

Talmud PJ (2001) Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr Atheroscler Rep 3:191–199PubMed

90.

Ebra T, Conde K, Kako Y et al. (2000) Delayed catabolism of apo B48 lipoproteins due to decreased heparin sulphate proteoglycan production in diabetic mice. J Clin Invest 105:1807–1818PubMed

91.

Haidari M, Leung N, Mahbub F et al. (2002) Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. J Biol Chem 277:31646–31655CrossRefPubMed

92.

Fard A, Tuck CH, Donis JA et al. (2000) Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20:2039–2044

93.

Evans M, Anderson RA, Graham J et al. (2000) Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101:1773–1779PubMed

94.

Rongen GA, Tack CJ (2001) Triglycerides and endothelial function in type 2 diabetes. Eur J Clin Invest 31:560–562CrossRefPubMed

95.

Ceriello A, Taboga C, Tonutti L et al. (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 106:1211–1218CrossRefPubMed

96.

Flood C, Gustafsson M, Richardson PE et al. (2002) Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 277(35): 32228–32233CrossRefPubMed

97.

Skålen K, Gustafsson M, Rydberg EK et al. (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417:750–754CrossRefPubMed

98.

Doi H, Kugiyama K, Oka H et al. (2000) Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102:670–676PubMed

99.

Anderson RA, Jones CJH, Goodfellow J (2001) Hypothesis: is the fatty meal a trigger for acute coronary syndromes. Atherosclerosis 159:9–15CrossRefPubMed

100.

Austin MA, Breslow JL, Hennekens CH et al. (1988) Low-density lipoprotein subclass patterns and risk of myocardial infraction. JAMA 260:1917–1921PubMed

101.

Hurt-Camejo E, Camejo G, Sartipy P (2000) Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 11:465–471CrossRefPubMed

102.

Otvos JD, Jayarajah EJ, Cromwell WC (2002) Measurements issues related to lipoprotein heterogeneity. Am J Cardiol 90 [Suppl]:I22–I29

103.

Boren J, Lee I, Zhu W et al. (1998) Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective Apo-B100. J Clin Invest 101:1084–1093PubMed

104.

Sniderman AD, Scantlebury T, Cianflone K (2001) Hypertriglyceridemic HyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:447–459PubMed

105.

Tilly-Kiesi M, Syvänne M, Kuusi T et al. (1992) Abnormalities of low density lipoproteins in normolipidemic type 2 diabetic and nondiabetic patients with coronary artery disease. J Lipid Res 33:333–342PubMed

106.

Stewart MW, Laker MF, Dyer RG et al. (1993) Lipoprotein compositional abnormalities and insulin resistance in type 2 diabetic patients with mild hyperlipidemia. Arterioscl Thromb Vasc Biol 13:1046–1052

107.

Lahdenperä S, Syvänne M, Kahri J et al. (1996) Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39:453–461CrossRefPubMed

108.

Gray RS, Robbins DC, Wang Wenyu et al. (1997) Relation of LDL size to the insulin resistance syndrome and coronary heart disease in american indians. Arterioscler Thromb Vasc Biol 17:2713–2720PubMed

109.

Feingold KR, Grunfield C, Pang M et al. (1992) LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496–1502PubMed

110.

Caixàs A, Ordóñez-Llanos J, Leiva A de et al. (1997) Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 46:1207–1213PubMed

111.

Koba S, Hirano T, Yoshino G et al. (2002) Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. Atherosclerosis 160:249–256CrossRefPubMed

112.

Lahdenperä S, Sane T, Vuorinen-Markkola H et al. (1994) LDL particle size in mildy hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. Atherosclerosis 113:227–236CrossRef

113.

Tchernof A, Moorjani S, Lamarche B et al. (1996) The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19:629–637PubMed

114.

Ambrosch A, Dierkes J, Mühlen I et al. (1998) LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects. Diabetes Care 21:2077–2084PubMed

115.

Rainwater DL (2000) Lipoprotein correlates of LDL particle size. Atherosclerosis 148:151–158CrossRefPubMed

116.

Austin MA, Breslow JL, Hennekens CH et al. (1988) Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917–1921PubMed

117.

Coresh J, Kwiterovich PO, Smith HH et al. (1993) Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34:1687–1697PubMed

118.

Lamarche B, Tchernof A, Dagenals GR et al. (1997) Small, dense LDL particles and the risk of ischemic heart disease. Prospective results from the Québec Cardiovascular Study. Circulation 95:69–75PubMed

119.

Gardner CD, Fortmann SP, Krauss RM (1996) Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875–881CrossRefPubMed

120.

St-Pierre AC, Ruel IL, Cantin B et al. (2001) Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104:2295–2299PubMed

121.

Vakkilainen J, Steiner G, Ansquer J-C et al. (2003) Relationships between LDL particle size, plasma lipoproteins and progression of coronary artery disease. The diabetes atherosclerosis intervention study (DAIS). Circulation 107:1733–1737CrossRefPubMed

122.

Hogikyan RV, Galecki AT, Pitt B et al. (1998) Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes. J Clin Endocr Metab 83:1946–1952PubMed

123.

Tan KC, Ai VH, Chow S et al. (1999) Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 84:3212–3216PubMed

124.

Vakkilainen J, Mäkimattila S, Seppälä-Lindroos A et al. (2000) Endothelial dysfunction in men with small LDL particles. Circulation 102:716–721PubMed

125.

Mäkimattila S, Mäntysaari M, Liu M-L et al. (1999) Impaired endothelium-dependent vasodilation in type 2 diabetes. Diabetes Care 22:973–981PubMed

126.

Chapman MJ, Guérin M, Bruckert E (1998) Atherogenic, dense low-density lipoproteins: Pathophysiology and new therapeutic approaches. Eur Heart J 19 [Suppl A]:A24–A30

127.

Kornerup K, Nordestgaard BG, Feldt-Rasmussen B et al. (2002) Transvascular low-density lipoprotein transport in patients with diabetes mellitus (type 2): a noninvasive in vivo isotope technique. Arterioscler Thromb Vasc Biol 22:1168–1174CrossRefPubMed

128.

Galeano NF, Milne R, Marcel YL et al. (1994) Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 269:511–519PubMed

129.

Anber V, Griffin BA, Mc Connell M et al. (1996) Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261–271CrossRefPubMed

130.

Galeano NF, Al-Haideri M, Keyserman F et al. (1998) Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenity. J Lipid Res 39:1263–1273PubMed

131.

Chait A, Wight TN (2000) Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr Opin Lipidol 11:451–456CrossRefPubMed

132.

Tribble DL, Holl LG, Wood PD et al. (1992) Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93:189–199PubMed

133.

De Graaf J, Lemmers HLM, Hectors MPC et al. (1991) Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:198–306PubMed

134.

Lyons TJ, Jenkins AJ (1997) Lipoprotein glycation and its metabolic consequences. Current Opin Lipidol 8:174–180

135.

Onorato JM, Jenkins AJ, Thorpe SR et al. (2000) Pyridoamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridocamine. J Biol Chem 275:21177–21184CrossRefPubMed

136.

Dimitriadis E, Griffin M, Owens D et al. (1996) Lipoprotein composition in NIDDM. The effect of dietary oleic acid on composition and oxidisability and function of low and high density lipoproteins. Diabetologia 39:667–676CrossRefPubMed

137.

Scheffer PG, Bakker SJL, Popp-Snijders C et al. (2001) Composition of LDL determinant on its susceptibility to in vitro oxidation in patients with well-controlled type 2 diabetes. Diabetes Metab Res Rev 17:459–466CrossRefPubMed

138.

Chancharme L, Thérond P, Nigon F et al. (1999) Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler Thromb Vasc Biol 19:810–820PubMed

139.

Goldberg IJ (2001) Diabetic dyslipidemia: causes and consequences. J Clin Endocrin Metab 86:965–971

140.

Syvänne M, Ahola M, Lahdenperä S et al. (1995) High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 36:573–582PubMed

141.

Pascot A, Lemieux I, Prud'homme D et al. (2001) Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 42:2007–2014PubMed

142.

Syvänne M, Kahri J, Virtanen KS et al. (1995) HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92(3):364–370PubMed

143.

Syvänne M, Castro G, Dengremont C et al. (1996) Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 127:245–253CrossRefPubMed

144.

Lamarche B, Rashid S, Lewis G F et al. (1999) HDL metabolism in hypertriglyceridemic states: an overview. Clin Chem Acta 286:145–161CrossRef

145.

Lamarche B, Uffelman KD, Carpentier A et al. (1999) Triglyceride enrichement of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 103:1191–1199PubMed

146.

Rashid S, Barrett HR, Uffelman KD et al. (2002) Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol 22:483–487

147.

Golay A, Zech L, Shi A-Z et al. (1987) High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65:512–518PubMed

148.

Frénais R, Ouguerran K, Maugeais C et al. (1997) High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotype study. Diabetologia 40:578–583CrossRefPubMed

149.

Pietzsch J, Juselius U, Nitzsche S et al. (1998) In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47:1928–1934PubMed

150.

Frénais R, Nazih H, Ouguerram K et al. (2001) In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 86:1962–1967PubMed

151.

Von Eckardstein A, Nofer J-R, Assmann G (2001) High density lipoproteins and arteriosclerosis, role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13–27PubMed

152.

Tu A-Y, Albers JJ (2001) Glucose regulates the transcriptions of human genes relevant to HDL metabolism: Responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50:1851–1856PubMed

153.

Riemens SC, Tol A van, Sluiter WJ et al. (1999) Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration. Diabetes 48:1631–1637PubMed

154.

Miettinen H, Haffner SM, Lehto S et al. (1998) Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21:69–75PubMed

155.

Mukamai KJ, Maclure M, Nesto RW et al. (2001) Impact of diabetes on long-term survival after acute myocardial infarction. Diabetes Care 24:1422–1427PubMed

156.

Haffner SM (2003) Management of dyslipidemia in adults with diabetes. Diabetes Care 26 [Suppl]:S83–S86

157.

Pyörälä K, Pedersen TR, Kjekshus J et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20:614–621PubMed

158.

Goldberg RB, Mellies MJ, Sacks FM et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98:2513–2519PubMed

159.

Sacks FM, Tonkin AM, Craven T et al. (2002) Coronary heart disease in patients with with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105:1424–1428CrossRefPubMed

160.

Heart Protection Study Collaborative Group (2002) MRC/BHF heart production study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefPubMed

161.

Armitage J, Collins R (2000) Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart 84:357–360CrossRefPubMed

162.

U.K. Prospective diabetes study group (1997) Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20:1683–1687PubMed

163.

Diabetes atherosclerosis intervention study investigators (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis intervention study, a randomised study. The Lancet 357:905–910CrossRef

164.

Gotto A, Farmer J A (2001) Pleiotropic effects of stations: do they mater? Curr Opin Lipidol 12:391–394

165.

McFarlane S I, Muniyappa R, Francisco R et al. (2002) Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87(4):1451–1458PubMed

166.

Liao JK (2002) Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86:5–18CrossRefPubMed

167.

Bloomfield Rubins H, Robins SJ, Collins D et al. (2002) Diabetes, Plasma insulin and cardiovascular disease. Arch Intern Med 162:2597–2604CrossRefPubMed

168.

Fruchart J-C, Duriwz P, Staels B (1999) Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245–257PubMed

169.

Fruchart J-C, Staels B, Duriez P (2002) PPAR-alpha, lipoprotein metabolism, metabolic diseases and atherosclerosis. In: Fruchart J-C, Gotto AM Jr, Paoletti R, Staels B, Catapano AL (eds) Peroxisome Proliferator Activated Receptors: from basic science to clinical applications,18. Kluwer, Dordrecht, pp 63–79

170.

Chinetti G, Lestavel S, Bocher V et al. (2001) PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53–58PubMed

171.

Singaraja RR, Fievet C, Castro G et al. (2002) Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 110:35–42CrossRefPubMed

172.

Martens F, Visseren F, Lemay J et al. (2002) Metabolic and additional vascular effects of thiazolidinediones. Drugs 62:1463–1480PubMed

173.

Duval C, Chinetti G, Trottein F et al. (2002) The role of PPARs in atherosclerosis. TRENDS in Molecular Medicine 8:422–430CrossRefPubMed

174.

Etgen GJ, Oldham BA, Johnson WT et al. (2002) A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51:1083–1087PubMed

175.

Lindén D, Lindberg K, Oscarsson J et al. (2002) Influence of peroxisome proliferator-activated receptor α agonist on the intracellular turnover and secreation of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem 277:23044–23053CrossRefPubMed

176.

Sugden MC, Bulmer K, Gibbons GF et al. (2002) Peroxisome-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem J 364:361–368CrossRefPubMed

177.

Mayerson AB, Hundal RS, Dufour S et al. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797–802PubMed

178.

Nichols AV, Krauss RM, Musliner TA (1986) Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol 128:417–431PubMed

Titel: Diabetic dyslipidaemia: from basic research to clinical practice*
verfasst von: Dr. M.-R. Taskinen
Publikationsdatum: 01.06.2003
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2003
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-003-1111-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diabetic dyslipidaemia: from basic research to clinical practice*

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2003

Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis

Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes

Keratinocyte growth factor and beta-cell differentiation in human fetal pancreatic endocrine precursor cells

Multiple autoantibodies as predictors of Type 1 diabetes in a general population

Ectopic expression of the beta-cell specific transcription factor Pdx1 inhibits glucagon gene transcription

The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin